Also known as: Azacytidine
Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Azacitidine is the active ingredient of these drugs:
Austria
Australia Hong Kong Singapore
Australia
Austria Poland
Ireland Lithuania Poland United States
Australia Austria Brazil Canada Cyprus
Brazil
Hong Kong Singapore
Poland
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):